With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead Sciences, Hookipa Pharma has ...

A Trump administration proposal to consider another form of drugs for Medicare price cuts is spurring legal and policy ...

Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda. The move adds to a growing list ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical innovation is redefining treatment, prevention, and chronic disease care ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the ...

Gilead’s daily antiviral pills can prevent HIV transmission and slow AIDS. While an HIV vaccine remains the Holy Grail, Gilead’s new long-lasting injection, lenacapavir, is the next best thing.

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

Gilead Sciences drug lenacapavir, brand name Yeztugo, is now approved for HIV pre-exposure prophylaxis. The twice injectable medication is hoped to improve uptake and adherence to PrEP.

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more t… ...

Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a convenient new way to ward off infection in a wide range of people.